Technology
Health
Pharmaceutical

BioDelivery

$4.39
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.04 (-0.90%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell BioDelivery and other stocks, options, ETFs, and crypto commission-free!

About

BioDelivery Sciences International, Inc. operates as a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. It focuses on pharmaceutical products in the areas of pain management and addiction. Read More The company was founded in 1997 and is headquartered in Raleigh, NC.

Employees
164
Headquarters
Raleigh, North Carolina
Founded
1997
Market Cap
333.66M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
681.67K
High Today
$4.48
Low Today
$4.35
Open Price
$4.44
Volume
269.10K
52 Week High
$5.37
52 Week Low
$2.31

Collections

Technology
Health
Pharmaceutical
Therapy
Medical
US
North America

News

Seeking AlphaMay 10

BioDelivery's Bang Up Quarter

We take a deeper look at the company and its recent rock-solid results in the paragraphs below. One of the more impressive came from BioDelivery Sciences, which may have been overlooked by investors as equities slid on trade tensions. A myriad of Q1 results have been posted this week from small biotech/biopharma stocks amidst this week's pullback in the market. "A vote is like a rifle: its usefulness depends upon the character of the user.” - Theodore Roosevelt It has been a rocky week so far. Escalatin...

404
NasdaqMay 7

BioDelivery (BDSI) Stock Up on Q1 Earnings and Sales Beat

BioDelivery Sciences International, Inc. BDSI incurred a loss of 5 cents per share for first-quarter 2019, narrower than the Zacks Consensus Estimate of a loss of 8 cents. In the year-ago quarter, the company had incurred a loss of 18 cents per share. Revenues totaled $19.8 million, up 75.2% from the year-ago period figure and 10% sequentially. The uptick was mainly driven by higher sales of Belbuca. The top line also outpaced the Zacks Consensus Estimate of $19.6 million. Following the better-than-expect...

81
Yahoo FinanceMay 7

Edited Transcript of BDSI earnings conference call or presentation 6-May-19 8:30pm GMT

Q1 2019 BioDelivery Sciences International Inc Earnings Call RALEIGH May 7, 2019 (Thomson StreetEvents) -- Edited Transcript of BioDelivery Sciences International Inc earnings conference call or presentation Monday, May 6, 2019 at 8:30:00pm GMT TEXT version of Transcript ================================================================================ Corporate Participants ================================================================================ * Herm Cukier BioDelivery Sciences International...

42

Earnings

-$0.29
-$0.21
-$0.13
-$0.05
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.